Pirfenidone for Pulmonary Fibrosis in Patients With CKD Does

Pirfenidone for Pulmonary Fibrosis in Patients With CKD Does Not Hike Mortality

Patients with idiopathic pulmonary fibrosis and CKD have limited options for antifibrotic therapy. An observational study examined the use of the antifibrotic pirfenidone in patients with kidney disease (CKD) and pulmonary fibrosis.

Related Keywords

South Korea , Seoul , Soult Ukpyolsi , Bucheon , Kyonggi Do , Korea , Yong Hyun Kim , Korean National Health Insurance Service , Catholic University Of Korea , Catholic University , National Health Insurance Service ,

© 2025 Vimarsana